Last updated on August 2017

Study of CLR 131 in Relapsed or Refractory Select B-Cell Malignancies


Brief description of study

This study evaluates CLR 131 in patients with select B-cell malignancies (multiple myeloma( MM), indolent chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), lymphoplasmacytic lymphoma (LPL), marginal zone lymphoma (MZL), mantle cell lymphoma (MCL), and diffuse large B-cell lymphoma (DLBCL) who have been previously treated with standard therapy for their underlying malignancy.

Clinical Study Identifier: NCT02952508

.

Contact Investigators or Research Sites near you

Start Over

Please choose location

View all locations

Kate Oliver

Cellectar Biosciences site
Jacksonville, FL United States
  Connect »

Kate Oliver

Cellectar Biosciences site
Maywood, IL United States
  Connect »

Kate Oliver

Cellectar Biosciences site
New Orleans, LA United States
  Connect »

Kate Oliver

Cellectar Biosciences site
Rochester, NY United States
  Connect »

Kate Oliver

Cellectar Biosciences
Greenville, SC United States
  Connect »

Kate Oliver

Cellectar Biosciences site
Seattle, WA United States
  Connect »